Part B Reform: HHS Proposal Is Intriguing – But Bigger Message Is Timing
“Immediate” actions on drug pricing reform aren’t necessarily happening soon, given that the competitive bidding proposal is just a request for information.
You may also be interested in...
CMS using authority from previously abandoned competitive acquisition program; vendors may get ability to use formularies and apply utilization management techniques like prior authorization and step therapy.
Distributors, specialty pharmacies and PBMs are in a better position now to act as vendors then they were a decade ago, when Medicare unsuccessfully tried to implement a Medicare Part B prescription drug competitive acquisition program, HHS Secretary Azar points out.
Lilly’s view of the impact of the pending US drug pricing reform legislation is that it will require rethinking of all its small molecule development programs. That may sound extreme, but it is a logical response to the incentives in the bill. Does that mean the end of the generic drug era?